Supatret-C is relevant for the symptomatic management of acne vulgaris. This treatment is applicable in instances where symptoms relate to inflammatory or irritative states. It is commonly used when short-term symptomatic assistance is needed to address specific manifestations, including papules, pustules, and comedones.

---

This medicine is considered relevant in situations involving recurrent or episodic manifestations, applied in addressing symptoms that interfere with daily functioning. It is applied during phases of increased discomfort where supportive relief is relevant. It may be part of symptomatic management for symptom clusters that may become intense or disruptive, assisting with maintaining functional stability.

---

Relevant in contexts marked by increased discomfort or tension, this treatment is commonly used across conditions presenting with acute episodes. It may assist with managing multiple symptoms that occur together, contributing to easing the overall symptom load. By supporting the patient through acute episodes, it helps maintain a sense of stability when symptoms become more noticeable and supports general well-being during symptomatic phases.

Quick Fact: Support for Inflammatory Lesions This topical treatment is relevant for easing symptoms associated with inflammatory states that create noticeable physiological strain.

Regulatory References

1. NIH DailyMed official drug label

The official eligibility for the Clindamycin-Tretinoin topical gel (Supatret-C) is formally defined by regulatory authorities and is determined by a patient’s age and specific pre-existing medical conditions.

The medicine is contraindicated and must not be used by patients with a history of Regional Enteritis, Ulcerative Colitis, or Antibiotic-Associated Colitis. Use is also prohibited for individuals with a known hypersensitivity to clindamycin or lincomycin.

Supatret-C is formally approved for use in patients 12 years of age and older. The regulatory labeling specifies that safety and effectiveness have not been established in two populations: children under 12 years of age and the geriatric population (65 years and older).

Regarding physiological states, the medicine's use during pregnancy is restricted under the FDA's Category C classification, permitting use only if the potential benefit justifies the potential risk. For lactating mothers, official guidance requires a formal decision to discontinue nursing or discontinue the drug. No specific restrictions related to organ function, such as hepatic or renal impairment, are explicitly documented in the primary labeling for this topical Fixed-Dose Combination (FDC).

Interactions with other medicines and products

This section summarizes interaction patterns for the Supatret-C fixed-dose combination, as officially documented in government regulatory sources. As a topical preparation, the potential for systemic drug-drug interactions is generally limited; however, specific local and systemic interactions are formally restricted.

---

Contraindicated Combinations (Prohibited Co-administration)

Co-administration with the following products is strictly prohibited:

• Erythromycin-containing topical preparations: This combination is contraindicated due to the potential for cross-resistance between the lincosamide component (Clindamycin) and macrolides.
• Other topical retinoids (e.g., Adapalene, Tazarotene): Co-administration is contraindicated due to the risk of an additive irritant effect.

---

Pharmacodynamic and Timing Restrictions

Interactions involving an additive effect or reduction in efficacy require specific constraints on use:

• Products containing Benzoyl Peroxide may reduce the effectiveness of the Clindamycin component. The official labeling mandates separation of administration timing for these agents.
• Other topical preparations that are known to cause local irritation, such as abrasive soaps, peeling agents, sulfur, resorcinol, or salicylic acid, are noted to produce an additive irritant effect.

---

Systemic Effect Enhancement

The Clindamycin component possesses intrinsic neuromuscular blocking properties. Co-administration of the topical preparation with Neuromuscular Blocking Agents (NMBAs) may formally enhance the action of the blocking agent.

The action of Supatret-C is based on the complementary synergy of two active ingredients that influence distinct but interconnected physiological processes within the pilosebaceous unit. This mechanism involves simultaneous modulation of microbial proliferation and regulation of epithelial cell dynamics.

---

Modulation of Microbial Proliferation via 50S Ribosomal Inhibition

This domain describes how the Clindamycin component exerts a bacteriostatic effect by specifically targeting the 50S ribosomal subunit of P. acnes. Binding to this structure arrests the translocation step, suppressing bacterial protein synthesis and limiting proliferation. This action directly modulates the inflammatory mediator pathway by reducing the population of microorganisms and their metabolic byproducts, contributing to the modulation of local inflammatory signaling.

---

Nuclear Receptor Agonism and Regulation of Follicular Cell Differentiation

The Tretinoin component engages a different domain by acting as an agonist for intranuclear Retinoic Acid Receptors (RARs). This mechanism alters the gene transcription patterns in keratinocytes, influencing the state of follicular hyperkeratinization. This process supports the regulation of epithelial cell differentiation and cohesion, promoting the necessary shedding (desquamation) of follicular cells and contributing to a modified structure within the follicular canal.

Administration Guidelines for Supatret-C

Supatret-C is a fixed-dose combination gel containing clindamycin and tretinoin, and its administration is defined by standardized guidelines for use.

Category	Official Use Principle
Route of Administration	The preparation is for topical use only and must not be used orally, ophthalmicly, or intravaginally.
Dosing Schedule	The standard regimen is a once-daily application of approximately a pea-sized amount of the gel to the entire affected area. Use of a greater quantity or higher frequency is not recommended.
Timing	Application should occur in the evening or at bedtime for optimal procedural consistency.
Preparation	Prior to use, the skin must be gently washed with a mild soap and water, and subsequently patted dry. The gel should only be applied to dry skin.
Age-Group Rules	This topical gel is indicated for use in patients 12 years of age and older.

---

Special Procedural Conditions

The administration guidelines stipulate several key procedural constraints related to the application site and environment. The gel must be applied only to the entire affected area and kept away from the eyes, mouth, lips, and mucous membranes to prevent incorrect absorption. Furthermore, the established parameters mandate that patients must avoid exposure to sunlight and sunlamps during the entire course of use. A broad-spectrum sunscreen must be applied every morning and reapplied throughout the day. These instructions establish the necessary external conditions and parameters for standardized administration, ensuring the required pattern of use is followed.

Research Evidence / Overview of Studies

Studies on Lesion Counts and Severity

Clinical research has evaluated whether the fixed-dose combination of clindamycin and tretinoin is associated with changes in acne lesion counts and overall severity. These investigations typically use standardized measures, such as the Investigator's Global Assessment (IGA) score, to assess severity, and quantify non-inflammatory (e.g., comedones) and inflammatory lesions (e.g., papules, pustules).

• Short-Term Trials: Multiple 12-week, randomized, controlled trials have examined the formulation's performance. Findings from these trials indicate that the combination was associated with a greater percentage reduction in total lesions—including both inflammatory and non-inflammatory types—compared to using clindamycin or tretinoin monotherapies alone.
• Treatment Success: Studies report that a greater percentage of participants achieved a successful outcome, often defined as 'Clear' or 'Almost Clear' on the IGA scale, when using the combination product compared to its individual components.

Research on Components and Mechanism

Research has explored the complementary roles of the two active ingredients. The clindamycin component, an antibiotic, is investigated for its potential role in managing Cutibacterium acnes (the bacterium formerly known as Propionibacterium acnes). Tretinoin, a retinoid, is researched for its influence on follicular keratinization and cell turnover.

• Comparative Efficacy: Research consistently suggests that combining the two agents in a single formulation may provide a more comprehensive approach by simultaneously addressing both the inflammatory (bacterial) and comedolytic (cell turnover) factors associated with acne.

Research Limitations and Scope

The findings from clinical research may be influenced by study design, participant characteristics, and measured endpoints. Most pivotal trials are 12 weeks in duration, focusing on short-term efficacy and tolerability.

• Evidence Gaps: The full scope of benefits and long-term effects beyond the typical 12-week study period is an area where evidence remains limited. Ongoing research continues to explore the range of potential applications and outcomes, especially regarding long-term maintenance of results.

Common questions about Supatret-C (FAQ)

Q: How long does it usually take to see a difference after starting Supatret-C?

A: Official documentation notes that therapeutic improvement may not be observed for several weeks after starting treatment. Clinical trials often assess the drug's performance over a period of about 12 weeks.

Q: Is it normal to experience dryness when first applying Supatret-C?

A: Official safety information indicates that dryness at the application site is a commonly reported side effect. This reaction is often expected, especially during the initial stages of therapy as the skin adjusts to the ingredients.

Q: Is the peeling effect associated with Supatret-C normal?

A: Scaling, skin peeling, and exfoliation are frequently reported skin reactions. These effects, classified as common adverse events, are associated with the use of the combination product.

Q: Can Supatret-C be used during the summer months?

A: Official guidelines mandate that exposure to natural sunlight, sunlamps, and tanning beds must be minimized or avoided throughout the treatment period. If sun exposure cannot be entirely avoided, official guidelines mandate the daily use of a broad-spectrum sunscreen and protective clothing.

Q: What happens if I miss an application of Supatret-C?

A: Regulatory documents provide clear guidance for a forgotten dose. Official instructions specify that an extra application should not be performed to make up for the forgotten dose. The next application should be performed at the usual scheduled time.

Q: Can I use other topical creams at the same time as Supatret-C?

A: Official documentation advises caution regarding the co-administration of topical products. The preparation should not be used simultaneously with other topical retinoids, erythromycin-containing products, or any preparations known to cause local irritation.

Q: What does the 'C' stand for in Supatret-C?

A: The product is a fixed-dose combination containing two active ingredients: Clindamycin and Tretinoin. This distinguishes it from preparations containing Tretinoin alone.

Q: Can people with sensitive skin use Supatret-C?

A: The product is advised to be prescribed with caution in individuals classified as atopic subjects, which refers to those with a genetic tendency to develop allergic diseases. Application to sensitive areas of skin should also be made with caution.

Q: What category of drug does Supatret-C fall under?

A: Supatret-C is classified as a fixed-dose combination dermatological product. It contains both a topical antibiotic (Clindamycin) and a retinoid (Tretinoin).

Q: Does the efficacy of Supatret-C decrease over time?

A: Official warnings note a concern related to the long-term use of the clindamycin component. Prolonged use may cause resistance or the overgrowth of non-susceptible dermal bacteria or fungi.

Q: Are there different strengths of Supatret-C available?

A: The specific fixed-dose combination product is typically available in a single approved strength, such as 1.2% Clindamycin and 0.025% Tretinoin.

Q: Are headaches a known side effect of Supatret-C?

A: Based on clinical trial data, headaches are classified as an uncommon or rare side effect associated with the use of the topical combination product. They are not among the most frequently reported topical skin reactions.

Q: Is Supatret-C available over the counter in some countries?

A: Official documents from regulatory bodies designate this product as a prescription-only medicine (Rx) in its approved territories.

Q: Is Supatret-C considered safe for long-term use?

A: Regulatory documents state that continuous treatment with the product should generally not exceed 12 weeks without careful re-evaluation by a healthcare provider.

Q: Has Supatret-C been studied in younger children or adolescents?

A: The official labeling specifies that safety and effectiveness have not been established for use in children under 12 years of age.

Q: Is there a generic version of Supatret-C?

A: The active ingredient combination, clindamycin and tretinoin topical gel, is documented in the market to have generic versions available.

Q: Does Supatret-C have a specific expiration period once opened?

A: Official labeling and the Summary of Product Characteristics formally document a shelf-life after the container is first opened. This period can vary by region and formulation, for example, often being specified as 3 months.

Q: Are allergic reactions to Supatret-C common?

A: A known hypersensitivity to the active ingredients or related compounds is listed as a contraindication, meaning the drug must not be used. Additionally, certain non-active ingredients in the gel are noted in documentation as having the potential to cause allergic reactions.

Q: Can Supatret-C be used by people with a history of liver problems?

A: Official documentation notes that moderate hepatic (liver) impairment is not expected to result in systemic exposure of clinical concern.

Q: Are there any documented drug-alcohol interactions with Supatret-C?

A: Official regulatory safety information indicates that there are no documented drug-alcohol interactions specific to this topical product.

Q: How is the combination of ingredients in Supatret-C supposed to work together?

A: The action of the medicine is based on a complementary synergy of its two components. Clindamycin modulates microbial proliferation, and Tretinoin regulates epithelial cell differentiation and turnover.

How to Store and Dispose of Supatret-C?

The storage and disposal of Supatret-C Gel are strictly defined to maintain product stability and ensure safety, as outlined in official regulatory labeling.

---

Storage Requirements

Supatret-C Gel must be stored at a Controlled Room Temperature below 30 C (86 F). Do not freeze the product, and store it away from direct heat or open flame. The container must be kept tightly closed and stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Supatret-C must be disposed of according to local regulatory requirements for pharmaceutical waste, such as utilizing drug take-back programs. To protect the environment, do not pour the gel down a sink or toilet.